CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.52 HKD 1.19% Market Closed
Market Cap: 4.9B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CARsgen Therapeutics Holdings Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Change in Working Capital
ÂĄ229.9m
CAGR 3-Years
153%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Change in Working Capital
-ÂĄ12.8B
CAGR 3-Years
-278%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Change in Working Capital
ÂĄ558m
CAGR 3-Years
N/A
CAGR 5-Years
78%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Change in Working Capital
-ÂĄ3.9B
CAGR 3-Years
-70%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Change in Working Capital
-ÂĄ3.9B
CAGR 3-Years
-26%
CAGR 5-Years
-24%
CAGR 10-Years
-32%
Imeik Technology Development Co Ltd
SZSE:300896
Change in Working Capital
-ÂĄ496.4m
CAGR 3-Years
-43%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.9B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Change in Working Capital?
Change in Working Capital
229.9m CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Change in Working Capital amounts to 229.9m CNY.

What is CARsgen Therapeutics Holdings Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
153%

Over the last year, the Change in Working Capital growth was 451%. The average annual Change in Working Capital growth rates for CARsgen Therapeutics Holdings Ltd have been 153% over the past three years .

Back to Top